Joel E. Ahumada-Vargas

Mexico City, DIF, Mexico

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 8 publications

IgG4-Related Disease and Synchronous Marginal Zone Lymphoma Evaluated by 99mTc-iFAP SPECT/CT and [ 18 F]-FDG PET/CT: A Case Report.

IgG4-Related Disease and Synchronous Marginal Zone Lymphoma Evaluated by 99mTc-iFAP SPECT/CT and [ 18 F]-FDG PET/CT: A Case Report.

Journal: World journal of nuclear medicine

Published: May 04, 2026

The role of [18F]PSMA-1007 PET/CT in staging of prostate cancer: Influence of bone uptake and relationship with D'Amico risk classification.

The role of [18F]PSMA-1007 PET/CT in staging of prostate cancer: Influence of bone uptake and relationship with D'Amico risk classification.

Journal: Revista espanola de medicina nuclear e imagen molecular

Published: February 15, 2026

Carcinoid Heart Disease: A Classic One, But Not Always Remembered.

Carcinoid Heart Disease: A Classic One, But Not Always Remembered.

Journal: Cureus

Published: January 24, 2025

Theranostic Potential of the iPSMA-Bombesin Radioligand in Patients with Metastatic Prostate Cancer: A Pilot Study.

Theranostic Potential of the iPSMA-Bombesin Radioligand in Patients with Metastatic Prostate Cancer: A Pilot Study.

Journal: Pharmaceutics

Published: September 21, 2024

68Ga-DOTA-D-Alanine-BoroPro Radiotracer for Imaging of the Fibroblast Activation Protein in Malignant and Non-Malignant Diseases.

68Ga-DOTA-D-Alanine-BoroPro Radiotracer for Imaging of the Fibroblast Activation Protein in Malignant and Non-Malignant Diseases.

Journal: Pharmaceutics

Published: January 09, 2024

Diagnostic Performance of 99mTc-iPSMA SPECT/CT in the Initial Staging of Patients with Unfavorable Intermediate-, High-, and Very High-Risk Prostate Cancer: A Comparative Analysis with 18F-PSMA-1007 PET/CT.

Diagnostic Performance of 99mTc-iPSMA SPECT/CT in the Initial Staging of Patients with Unfavorable Intermediate-, High-, and Very High-Risk Prostate Cancer: A Comparative Analysis with 18F-PSMA-1007 PET/CT.

Journal: Cancers

Published: October 26, 2023

Multitarget Molecular Imaging in Metastatic Castration Resistant Adenocarcinoma Prostate Cancer with Therapy Induced Neuroendocrine Differentiation.

Multitarget Molecular Imaging in Metastatic Castration Resistant Adenocarcinoma Prostate Cancer with Therapy Induced Neuroendocrine Differentiation.

Journal: Diagnostics (Basel, Switzerland)

Published: March 16, 2022

Head-to-Head Comparison of 68Ga-PSMA-11 and 131I in the Follow-Up of Well-Differentiated Metastatic Thyroid Cancer: A New Potential Theragnostic Agent.

Head-to-Head Comparison of 68Ga-PSMA-11 and 131I in the Follow-Up of Well-Differentiated Metastatic Thyroid Cancer: A New Potential Theragnostic Agent.

Journal: Frontiers in endocrinology

Published: October 14, 2021

Showing 1-8 of 8

Last Updated: 09/26/2026